As China Continues to Open Market for Integrated Bio, Agilent Ups Investment | GenomeWeb

In 2004, China became the No. 3 market for Agilent Technologies' life sciences unit, behind the US and Japan, respectively.

Recently, representatives of the Palo Alto, Calif.-based company told Chinese news agencies that Agilent will continue to increase activity in the country with a goal of investing $100 million over a five-year period as part of its strategy of reaching $10 billion in total revenues in the next three to five years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.